Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.80 |
| ▸ | JAK1 | P23458 | 13/20 | 0.80 |
| ▸ | JAK2 | O60674 | 11/20 | 0.80 |
| ▸ | TYK2 | P29597 | 2/20 | 0.67 |
| ▸ | SYK | P43405 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261149 | 0.99 | JAK3 (0.80) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL22261072 | 0.98 | JAK3 (0.80) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL22261159 | 0.96 | JAK3 (0.79) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL25421683 | 0.92 | JAK3 (0.68) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL22261399 | 0.91 | JAK3 (0.81) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL22261079 | 0.91 | JAK3 (0.81) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL22261346 | 0.90 | JAK3 (0.81) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL20844417 | 0.89 | JAK3 (0.68) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL25279257 | 0.89 | JAK3 (0.67) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL25424864 | 0.87 | JAK3 (0.67) | JAK3JAK1JAK2TYK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | claimed |
| CN-113214230-B | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-113214230-A | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2021-08-06 | — | — | CN | claimed |
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-03-18 | — | — | US | claimed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | claimed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.